N-Acetyl Semax — reference
Nootropic/neuroprotective peptide (Semax analog).
Regulatory status
Not FDA-Approved. Not FDA-approved in the US; approved as a prescription drug in Russia.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of Extended vs. Semax — marketed as ~2x longer, not independently verified. N-acetylation is claimed to slow degradation; no rigorous published PK comparison found.
This figure is tagged Not characterised in our evidence system. No reliable human pharmacokinetic data was found for this compound. We publish that fact rather than a number borrowed from an unreliable source. Any estimated curve here would be fiction, and should be treated as such. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is N-Acetyl Semax FDA-approved?
What is the half-life of N-Acetyl Semax?
How reliable is that half-life figure?
What cautions are associated with N-Acetyl Semax?
Does Peptide Plug publish dosing for N-Acetyl Semax?
Does Peptide Plug sell N-Acetyl Semax?
Related tools
Free, no account required.